Marinus Pharmaceuticals to Present Ganaxolone Clinical Trial Data in CDKL5 Deficiency Disorder and PCDH19-Related Epilepsy at...
November 19 2018 - 7:30AM
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”,
“Marinus”), a biopharmaceutical company dedicated to the
development of innovative therapeutics to treat epilepsy and
neuropsychiatric disorders, today announced that two abstracts
highlighting the results of clinical trials of ganaxolone in
children with CDKL5 Deficiency Disorder (CDD) and PCDH19-related
epilepsy have been selected for poster presentation at the American
Epilepsy Society (AES) Annual Meeting in New Orleans on December 2
and 3, 2018.
Details for the poster presentations at the AES
Annual Meeting:
“Long-term, Durable Seizure Frequency Reduction in
Individuals with CDKL5 Deficiency Disorder (CDD) Treated with
Ganaxolone,” N. Specchio, et al.Abstract #506062. Poster
session 3.283Monday, December 38:00 am to 2:00 pm, with authors
present from 12:00 Noon to 2:00 PM
“Preliminary Evidence of a Predictive Clinical Biomarker
in PCDH19-related Epilepsy: Significant Treatment Effect of
Ganaxolone In Biomarker-Positive Patients,” J.E. Sullivan,
et al.Abstract # 502507. Poster session 2.251Sunday, December
210:00 am to 4:00 pm, with authors present from 12:00 Noon to 2:00
PM
Marinus is also hosting a Scientific Poster Exhibit on Sunday,
December 2. At this exhibit, Marinus’ scientific and medical team
will be on-site to discuss ganaxolone and highlight preclinical and
clinical data from its clinical development programs in refractory
epileptic disorders, including rare genetic epilepsy and status
epilepticus.
What: Marinus Pharmaceuticals Scientific Exhibit
“Ganaxolone for the Treatment of Refractory Epileptic
Disorders”Where: Room 278-279 (2nd Floor)When: Sunday,
December 2, from 2:00 to 5:00 PM
About Marinus
Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a
biopharmaceutical company dedicated to the development of
ganaxolone, which offers a new mechanism of action, demonstrated
efficacy and safety, and convenient dosing to improve the lives of
patients suffering from epilepsy and neuropsychiatric disorders.
Ganaxolone is a positive allosteric modulator of GABAA that acts on
a well-characterized target in the brain known to have
anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone
is being developed in three different dose forms (IV, capsule and
liquid) intended to maximize therapeutic reach to adult and
pediatric patient populations in both acute and chronic care
settings. Marinus has initiated the first ever pivotal study
in children with CDKL5 deficiency disorder, a rare form of
epilepsy, and is currently conducting studies in patients with
postpartum depression and refractory status epilepticus. For more
information visit www.marinuspharma.com. Please follow us on
Twitter: @MarinusPharma.
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Marinus, they
are forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Words such as “may”, “will”, “expect”, “anticipate”, “estimate”,
“intend”, “believe”, and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking
statements. Examples of forward-looking statements contained
in this press release include, among others, statements regarding
our interpretation of preclinical studies, development plans for
our product candidate, including the development of dose forms, the
clinical trial testing schedule and milestones, the ability to
complete enrollment in our clinical trials, interpretation of
scientific basis for ganaxolone use, timing for availability and
release of data, the safety, potential efficacy and therapeutic
potential of our product candidate and our expectation regarding
the sufficiency of our working capital. Forward-looking statements
in this release involve substantial risks and uncertainties that
could cause our clinical development programs, future results,
performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Such risks
and uncertainties include, among others, the uncertainties inherent
in the conduct of future clinical trials, the timing of the
clinical trials, enrollment in clinical trials, availability of
data from ongoing clinical trials, expectations for regulatory
approvals, the attainment of clinical trial results that will be
supportive of regulatory approvals, and other matters, including
the development of formulations of ganaxolone, and the availability
or potential availability of alternative products or treatments for
conditions targeted by the Company that could affect the
availability or commercial potential of our drug candidates.
Marinus undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties that could cause actual results to differ from
those expressed in these forward-looking statements, as well as
risks relating to the business of the Company in general, see
filings Marinus has made with the Securities and Exchange
Commission.
CONTACT: Lisa M. CaperelliExecutive Director,
Investor & Strategic RelationsMarinus Pharmaceuticals,
Inc.484-801-4674lcaperelli@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Apr 2023 to Apr 2024